Medicare’s GLP-1 Bridge charges everyone the same: 50 dollars a month, from 1 July 2026 to the end of 2027, for one of three drugs. We read the eligibility rule yesterday. Today we read the payment rule, because a flat fee is never flat. The people who pay the least for every other prescription in Medicare are the ones for whom these 50 dollars weigh most, and the rule says so in its own words. This article is about how the money is built. It is not about the drugs, and it says nothing about whether anyone should take them.
What the fact sheet says in one paragraph
The Medicare fact sheet for beneficiaries (product number 12234, June 2026) needs three sentences for the whole payment design:
“Your cost for these drugs under this program is $50 per month, no matter your income level. This $50 payment doesn’t count toward your Medicare drug plan deductible or yearly out-of-pocket limit. These drugs aren’t eligible for the Medicare Prescription Payment Plan.”
Each of those sentences removes one of the three cushions that Medicare’s drug benefit otherwise puts under people with little money. The first removes the income-based subsidy. The second removes the annual cap. The third removes the option to spread the cost over the year. To see what that means, you need to know what those cushions are worth in 2026, and the agency publishes those numbers too.
What the cushions are worth in 2026
Medicare’s drug benefit, Part D, has a low-income subsidy, usually called Extra Help. The Centers for Medicare & Medicaid Services set its 2026 amounts in a memorandum to plan sponsors dated 31 October 2025. The table in that memo is short. People who qualify for the full subsidy pay no deductible. Their maximum copayment per prescription in 2026 is:
- 0 dollars, for people living in an institution or receiving home- and community-based services;
- 1.60 dollars for a generic and 4.90 dollars for a brand-name drug, for people on both Medicare and Medicaid with income at or below the federal poverty level;
- 5.10 dollars for a generic and 12.65 dollars for a brand-name drug, for everyone else who qualifies, which since 2024 means income up to 150 percent of the poverty level and countable resources of no more than 16,590 dollars (33,100 for a couple; 18,090 and 36,100 if some of it is set aside for burial).
The memo also states the second cushion. Footnote a to the table: “The out-of-pocket threshold is $2,100 for 2026.” Above that amount, “there is no cost-sharing for covered Part D drugs … for any Part D beneficiaries, including LIS-eligible beneficiaries.” That cap was created by the Inflation Reduction Act and took effect in 2024. It is the reason a Medicare patient with an expensive illness no longer pays without limit.
Now put the Bridge next to that table. A person whose brand-name copay is 4.90 dollars pays 50 dollars for a Bridge drug. That is the price of ten brand-name prescriptions under Extra Help, every month, for a single drug. A person in the 12.65-dollar tier pays the equivalent of four. A person in the institutional tier, who pays nothing for anything else, pays 50. Over the eighteen months the programme is scheduled to run, that is 900 dollars for each of them, and none of it moves them a cent closer to the 2,100-dollar cap.
Where the rule says it, and how
The fact sheet is written for patients. The version written for the insurers, the CMS page “Information for Part D Plans”, last modified 6 August 2026, is more technical and more complete. It explains that the Bridge “will operate outside of the Medicare Part D benefit’s coverage and payment flow.” Manufacturers supply the drugs “at a net price of $245 per monthly supply.” Then:
“No part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC), and no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan. In addition, the $50 copay for eligible beneficiaries would remain the same, regardless of the phase of the Part D benefit an eligible beneficiary is in when they fill a prescription for an eligible GLP-1 drugs covered under the Medicare GLP-1 Bridge. Similarly, low-income cost-sharing subsidies would also not apply to any portion of the copay.”
Three things follow from that paragraph that the fact sheet does not spell out.
First, “regardless of the phase” means the 50 dollars survive the cap. A patient who has already reached the 2,100-dollar threshold in, say, August, and who therefore pays nothing for any covered drug for the rest of the year, still pays 50 dollars for the Bridge drug in September, October, November and December. The cap protects everything except this.
Second, “any portion” means there is no partial subsidy. Extra Help does not reduce the 50 dollars to 12.65 or 4.90. It does not touch them.
Third, the same page rules out the usual workarounds. “Coupons and discount programs may not be applied to Medicare GLP-1 Bridge claims.” The Bridge “will not coordinate benefits with other payers.” And the fact sheet has already removed the Medicare Prescription Payment Plan, the instalment option Medicare introduced in 2025 so that a large bill can be spread across the year. The 50 dollars are due at the counter, in full, from everyone.
Is every subsidy tier affected?
We were asked to check this, because “low-income cost-sharing subsidies would not apply” could in principle mean the partial subsidy only. It does not. The Part D Plans page names no tier and no exception. The fact sheet says “no matter your income level.” The 31 October memo, which defines the tiers, does not mention the Bridge at all, which is what you would expect for a programme that sits outside the benefit the memo describes. We found no document in which CMS carves out any subsidy group, including the institutional tier that otherwise pays zero. If such a carve-out exists, it is not in the public rule as of 6 September 2026, and we will correct this article if one appears.
The Medicare Rights Center, a non-profit counselling service, read the rule the same way on 4 June 2026: “Cost assistance programs like Extra Help cannot be used, and the $50 copay stays the same, no matter what stage of Part D applies.”
The detail that reads like a joke
CMS chose a company to run the Bridge’s approvals, claims and pharmacy payments. The Part D Plans page names it: Humana, “the current administrator of the Limited Income Newly Eligible Transition (LI NET) program.” LI NET is the safety-net programme that gives newly eligible low-income people immediate drug coverage while their Extra Help paperwork catches up. CMS says it picked that infrastructure because it provides “the end-to-end operational capabilities and national scale” the Bridge needs. So the system built to make sure poor Medicare patients never pay full price at the pharmacy is the same system that will collect 50 dollars from them, every month, with no subsidy attached. Nobody designed that as irony. It is simply what happens when a programme is bolted on outside the benefit and borrows the nearest available plumbing.
Why the money is built this way
The reason is in the legal basis, which we described in the eligibility article and which the Part D Plans page repeats. The Bridge runs under Section 402 of the Social Security Amendments of 1967, which lets the Secretary test “changes in methods of payment or reimbursement.” It is a payment experiment. Part D itself is forbidden by statute from covering drugs prescribed for weight loss, so the Bridge cannot go through Part D, and if it does not go through Part D, none of Part D’s protections attach to it. The subsidy, the cap and the instalment plan are features of a benefit the Bridge is not part of. That is the whole explanation, and it is an honest one. It is also a choice: a demonstration could have set an income-tiered copay by its own rules. This one set a single price and called it access.
We have seen this shape before. In England, NICE’s TA1152 decides who gets in by body size and diagnosis, and the NHS then delivers at no charge. In France and Germany, the question is whether the public insurer pays at all, and the answer differs by country. The Bridge is the US variant: the public insurer pays most of the price, then charges a flat fee that the poorest cannot have reduced. It is not the cruellest arrangement on that list. It is the one that says “no matter your income level” as if that were the fair part.
What we are not saying
We are not saying how many people this affects. CMS publishes no figure for how many Bridge users receive Extra Help, and we are not going to estimate one. We are not saying whether 50 dollars is “affordable”; that depends on a budget we cannot see. And we are not saying anything about whether these drugs work or whether anyone should want them. Our subject is the payment rule, and the payment rule says, in the agency’s words, that the price is the same for everyone, that it counts toward nothing, and that the one mechanism Medicare has for lowering prices for the poor does not apply to any portion of it.
Sources
- Medicare, “Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month”, fact sheet, CMS Product No. 12234, June 2026. https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf (read in full; the three-sentence payment paragraph quoted from this document)
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, Information for Part D Plans (FAQ), page last modified 6 August 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans (read in full; TrOOP, benefit phase, subsidy, coupons, coordination of benefits, net price, central processor and Section 402 quoted from this page)
- Centers for Medicare & Medicaid Services, Medicare Plan Payment Group, “Calendar Year (CY) 2026 Resource and Cost-Sharing Limits for Low-Income Subsidy (LIS)”, HPMS memorandum to all Part D plan sponsors, 31 October 2025. https://www.cms.gov/files/document/cy2026-lis-resource-limits-memo.pdf (read in full; Table 2 copayments, resource limits and the 2,100-dollar threshold quoted from this document)
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, Information for Providers (FAQ), page last modified 6 August 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers (eligibility rule, covered in our previous article)
- Medicare Rights Center, “GLP-1 Weight-Loss Drug Demonstration Begins July 2026”, Medicare Watch, 4 June 2026. https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026 (secondary reading of the subsidy rule, quoted as such)